
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update on Sclerosing Mesenteritis: Commentary</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>AGA Clinical Practice Update on Sclerosing Mesenteritis: Commentary</strong></summary>
            <div>
                <ul><li>- Journal: Clinical Gastroenterology and Hepatology</li><li>- Publication Date: May 2025</li><li>- Link: https://doi.org/10.1016/j.cgh.2024.12.025</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the size cutoff for mesenteric lymph nodes that should raise suspicion for an underlying malignancy?</li><li>- What is the most commonly used therapy for SM, often in combination with prednisone, and what is its standard dosage?</li><li>- What percentage of patients with incidental SM findings on CT will eventually require treatment?</li><li>- What is the typical starting dose of prednisone for SM, and for how long is it usually continued before tapering?</li><li>- What is the most common symptom in patients with SM, and what percentage of symptomatic patients experience it?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Definition & Nomenclature</strong></summary>
            <div>
                <ul><li>- <b>Sclerosing Mesenteritis (SM)</b> is an uncommon disorder of the bowel mesentery.</li><li>- Characterized by a combination of <b>inflammation</b>, <b>fat necrosis</b>, and <b>fibrosis</b>.</li><li>- The etiopathophysiology is still <u>poorly understood</u>.</li></ul>
                
        <details>
            <summary><strong>Synonyms</strong></summary>
            <div>
                <ul><li>- Various terms likely represent a continuum of the same disease with differing ratios of the core pathological features.</li><li>- The unifying term <b>"sclerosing mesenteritis"</b> is proposed.</li><li>- Other terms include: Mesenteric panniculitis, retractile mesenteritis, “misty mesentery,” mesenteric lipodystrophy, liposclerotic mesenteritis.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Epidemiology</strong></summary>
            <div>
                <ul><li>- Frequency on retrospective CT studies: <q><u>0.6% to 1.1%</u></q>.</li><li>- Mean age at diagnosis: <q><b>55 years</b></q>.</li><li>- More likely to be <b>male</b> and of <b>White race</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Features</strong></summary>
            <div>
                <ul><li>- The diagnosis is increasingly common due to the widespread use of CT imaging for abdominal pain.</li></ul>
                
        <details>
            <summary><strong>Signs & Symptoms</strong></summary>
            <div>
                <ul><li>- Up to <q><b>60%</b></q> of patients with SM findings on CT are <u>asymptomatic</u>.</li><li>- Most common symptom: <b>Abdominal pain</b> (up to <q><u>75%</u></q>).</li><li>- Other symptoms: Bloating (10%–25%), diarrhea or constipation (10%–25%), nausea/vomiting (5%–15%), weight loss (20%).</li><li>- A palpable abdominal mass is often <u>not found</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Associated Conditions</strong></summary>
            <div>
                <ul><li>- Patients do <u>not</u> have a higher prevalence of autoimmunity.</li><li>- May have increased rates of: Metabolic syndrome, obesity, coronary artery disease, and urolithiasis.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- A presumptive diagnosis can often be made based on imaging without a biopsy, especially if there are no alarm features.</li></ul>
                
        <details>
            <summary><strong>Imaging (CT)</strong></summary>
            <div>
                <ul><li>- CT is the primary imaging modality for diagnosing SM.</li></ul>
                
        <details>
            <summary><strong>Coulier's CT Diagnostic Criteria</strong></summary>
            <div>
                <ul><li>- The presence of <u><b>3 or more</b></u> of these features is suggestive of SM.</li><li>- <b>1.</b> A hazy mesenteric fat mass displacing the intestine.</li><li>- <b>2.</b> Higher attenuation in the mass than adjacent mesentery (no enhancement with IV contrast).</li><li>- <b>3.</b> Presence of lymph nodes <q><b>< 1 cm</b></q>.</li><li>- <b>4.</b> A hypoattenuated <b>halo sign</b> around central vessels.</li><li>- <b>5.</b> A thin surrounding fibrotic <b>pseudocapsule</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Non-Diagnostic Findings</strong></summary>
            <div>
                <ul><li>- A hazy mesentery <u>without</u> nodes, halo sign, or pseudocapsule is <b>not diagnostic</b> for SM.</li><li>- If asymptomatic, these findings typically do not require follow-up.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Laboratory Findings</strong></summary>
            <div>
                <ul><li>- Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) may be elevated, but not in all cases.</li><li>- The role of these biomarkers in management or follow-up is <u>uncertain</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Biopsy</strong></summary>
            <div>
                <ul><li>- Definitive diagnosis requires biopsy, but it is often <u>unnecessary</u> if imaging is classic and there are no alarm features (fever, night sweats, unintentional weight loss).</li><li>- The risk of malignancy is very low in such cases.</li></ul>
                
        <details>
            <summary><strong>When to Biopsy</strong></summary>
            <div>
                <ul><li>- Consider biopsy for features concerning for <b>malignancy</b>.</li><li>- Also consider for calcifications and retraction of surrounding bowel, unless an association with IgG4 disease is established.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>IgG4-Related Disease</strong></summary>
            <div>
                <ul><li>- Rarely, SM can be a manifestation of IgG4-related disease, often with an <u>atypical presentation</u>.</li><li>- On CT, it can mimic malignancy with indistinct margins, invasion, and multiple enlarged lymph nodes.</li><li>- Only <q><b>half</b></q> of these patients have elevated serum IgG4 levels.</li><li>- A surgical biopsy with IgG4 staining may be required if IgG4 levels are normal but imaging is concerning.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Severe Disease & Differential Diagnosis</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Features Suggesting a More Severe Clinical Course</strong></summary>
            <div>
                <ul><li>- <b>Involvement</b>: Omental, retroperitoneal, pelvic fat, or colonic mesentery.</li><li>- <b>Complications</b>: Bowel obstruction/ischemia, venous thrombosis, sepsis, protein losing enteropathy, or renal failure.</li><li>- <b>Other</b>: Marked CRP/ESR elevations, coexisting autoimmune disease, arterial narrowing, ascites.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Differential Diagnosis</strong></summary>
            <div>
                <ul><li>- The differential includes other mesenteric conditions that are usually distinctly different on imaging.</li></ul>
                
        <details>
            <summary><strong>Non-Hodgkin Lymphoma</strong></summary>
            <div>
                <ul><li>- Can present with mesenteric infiltration or a mass lesion, difficult to distinguish from SM on imaging alone.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Peritoneal Carcinomatosis</strong></summary>
            <div>
                <ul><li>- Usually associated with ascites and multiple enhancing mesenteric, peritoneal, and/or omental nodules.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Carcinoid Tumor</strong></summary>
            <div>
                <ul><li>- Often associated with focal bowel and liver lesions.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Mesenteric Fibromatosis (Desmoid Tumors)</strong></summary>
            <div>
                <ul><li>- Commonly seen in <b>familial adenomatous polyposis</b> (FAP).</li><li>- Appear non-inflamed, mass-like, and can encase vessels.</li><li>- Preferred diagnostic test: <q><b>Magnetic resonance imaging (MRI)</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Encapsulating Peritoneal Sclerosis</strong></summary>
            <div>
                <ul><li>- Most common in <b>peritoneal dialysis</b> patients.</li><li>- Classic finding: 'cauliflower' or 'cocoon' appearance of encased bowel loops.</li><li>- Pockets of ascites occur in <q><b>90%</b></q>, and peritoneal calcifications in <q><b>70%</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Retroperitoneal Fibrosis</strong></summary>
            <div>
                <ul><li>- Soft tissue mass from L4-L5 to iliac arteries, encasing the ureters.</li><li>- Symptoms: Lower back or flank pain, distinct from the focal abdominal pain of SM.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pseudomyxoma Peritonei</strong></summary>
            <div>
                <ul><li>- Progressive intraperitoneal accumulation of mucinous ascites from a neoplasm (e.g., appendiceal).</li><li>- Classically results in a 'scalloped' appearance of coated organs.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Relationship with Cancer</strong></summary>
            <div>
                <ul><li>- Current evidence <u>does not support</u> SM being a paraneoplastic syndrome.</li><li>- However, there is an overlap with certain cancers, including <b>lymphoma</b>, gynecologic malignancies, and carcinoid tumors.</li></ul>
                
        <details>
            <summary><strong>Red Flags for Malignancy</strong></summary>
            <div>
                <ul><li>- Mesenteric mass or intra-abdominal lymph node <q><b>>10 mm</b></q> in size.</li><li>- Lymphadenopathy in another intra-abdominal location.</li><li>- Spiculated, necrotic, calcified, or invasive appearance.</li><li>- Absence of the central halo sign.</li></ul>
                
        <details>
            <summary><strong>Role of PET/CT</strong></summary>
            <div>
                <ul><li>- Helpful for characterization and identifying biopsy targets in suspicious cases.</li><li>- Lymph nodes with SUVmax <q><b>≥ 3.0</b></q> on 18FDG PET/CT are concerning.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk of Subsequent Malignancy</strong></summary>
            <div>
                <ul><li>- In a prospective study, the rate of subsequent malignancy was <q><b>1%</b></q>; all were B-cell lymphomas.</li><li>- These cases had either a soft tissue nodule >10 mm or abdominopelvic lymphadenopathy at baseline.</li><li>- Another study reported that <q><b>80%</b></q> of lymphomas were detectable within the <u>first year</u> of follow-up.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Immune Checkpoint Inhibitor-Associated SM</strong></summary>
            <div>
                <ul><li>- SM has been reported following cancer therapy with immune checkpoint inhibitors.</li><li>- It is often asymptomatic and generally responsive to <b>steroids</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>- Management is based on presentation; treatment is generally reserved for <b>symptomatic</b> patients.</li><li>- Fever should prompt an evaluation for infection before being attributed to SM.</li></ul>
                
        <details>
            <summary><strong>Asymptomatic Patients</strong></summary>
            <div>
                <ul><li>- Usually <u>not treated</u>.</li><li>- In several studies, only <q><b>1%–6%</b></q> of patients who presented with imaging findings of SM required treatment.</li></ul>
                
        <details>
            <summary><strong>Follow-Up Imaging</strong></summary>
            <div>
                <ul><li>- For asymptomatic cases without features concerning for malignancy, a suggested approach is <b>annual CT scans for 2 years</b> to ensure stability.</li><li>- Thereafter, imaging is performed only for concerning symptoms.</li><li>- Most patients achieve stable disease without radiologic progression after <q><b>2 years</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Symptomatic Patients</strong></summary>
            <div>
                <ul><li>- Therapy is aimed at <b>symptom relief</b>.</li><li>- There is limited evidence that treatment can improve imaging or prevent complications.</li></ul>
                
        <details>
            <summary><strong>General Measures</strong></summary>
            <div>
                <ul><li>- Treat concomitant GI disorders (e.g., constipation, GERD, IBS).</li><li>- <b>Tricyclic antidepressants</b> can be used for mild pain associated with SM.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>First-Line Medical Therapy</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Corticosteroids (Prednisone)</strong></summary>
            <div>
                <ul><li>- Monotherapy (<b>30–40 mg/day</b>) may improve short-term symptoms.</li><li>- Typical course: Start at <q><b>40 mg/day</b></q>, continue for <q><b>3–4 months</b></q>, then taper by 5 mg/week.</li><li>- Benefit is typically lost after drug discontinuation; long-term use is not advised.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Tamoxifen</strong></summary>
            <div>
                <ul><li>- The <u>most commonly used therapy</u>.</li><li>- Dose: <q><b>10 mg twice daily</b></q>, alone or with prednisone.</li><li>- Maximal response occurs around <q><b>4–6 months</b></q>, with a <q><b>50%–60%</b></q> response rate.</li><li>- When combined, prednisone is usually tapered after 3 months, and tamoxifen is continued for maintenance.</li></ul>
                
        <details>
            <summary><strong>Side Effects & Contraindications</strong></summary>
            <div>
                <ul><li>- <b>Side Effects</b>: Hot flashes, sweating, alopecia, fatigue, thrombosis, elevated liver enzymes.</li><li>- <b>Contraindications</b>: History of VTE, PE, or significant cardiovascular disease.</li><li>- Active tobacco use is a <u>relative</u> contraindication.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Medical Therapies</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Colchicine</strong></summary>
            <div>
                <ul><li>- Used with prednisone, with a response rate of around <q><b>50%</b></q>.</li><li>- Dose: <q><b>0.6 mg twice a day</b></q> with prednisone 40 mg daily (prednisone tapered after 3 months).</li><li>- Contraindicated in renal insufficiency.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Azathioprine</strong></summary>
            <div>
                <ul><li>- Dose: <q><b>2–2.5 mg/kg/day</b></q> in normal TPMT metabolizers.</li><li>- Has a slow onset of action, so co-administration with prednisone is used early in therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Second-Line Therapies</strong></summary>
            <div>
                <ul><li>- Reserved for severe, refractory disease due to potential for significant side effects.</li><li>- Agents with limited data include: Rituximab, thalidomide, cyclophosphamide, methotrexate, infliximab, and ustekinumab.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of Severe Disease & Complications</strong></summary>
            <div>
                <ul><li>- Surgery <u>does not cure</u> SM.</li><li>- In one study, only <q><b>10%</b></q> of patients who underwent surgery required no additional treatment.</li></ul>
                
        <details>
            <summary><strong>Bowel Obstruction</strong></summary>
            <div>
                <ul><li>- Managed with nonoperative management when feasible.</li><li>- If unsuccessful, surgical bypass may be required.</li><li>- Complete resection is usually impossible due to vascular compromise.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Chronic Ischemia</strong></summary>
            <div>
                <ul><li>- Caused by mesenteric vascular obstruction.</li><li>- Revascularization (endovascular or surgical) is rarely feasible.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Radiation Therapy</strong></summary>
            <div>
                <ul><li>- Has had <u>equivocal success</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-Surgery Management</strong></summary>
            <div>
                <ul><li>- For persistent or recurrent symptoms, medical management is suggested, similar to patients with non-obstructive symptoms.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Conclusions & Future Directions</strong></summary>
            <div>
                <ul><li>- SM is an idiopathic autoimmune disease of the mesenteric fat.</li><li>- Most cases are asymptomatic, do not require treatment, and can be followed.</li><li>- Biopsy is not required if CT criteria are met and there are no features of malignancy.</li><li>- There is <u>no surgical cure</u>.</li><li>- The most severe cases should be considered for referral to tertiary centers.</li></ul>
                
        <details>
            <summary><strong>Future Research</strong></summary>
            <div>
                <ul><li>- Future investigation should focus on the nature of the inflammatory response (e.g., causative cytokines).</li><li>- The goal is to develop targeted therapy with fewer side effects and a more rapid clinical response.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
